Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...
The Motley Fool6d
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force behind its strong numbers. It may not be long before Novo Nordisk also ...
Nasdaq6d
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
And the numbers speak for themselves: Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon. Founded in ...
AOL7d
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.